Novo Nordisk Faces Class Claims Over GLP-1 Patent Tactics

By Editorial Team

A South Carolina drug company has launched a proposed class action against major pharmaceutical company Novo Nordisk, alleging it engaged in anticompetitive behavior to prolong its monopoly against generic competition for the GLP-1 drug Victoza.

The lawsuit, filed in the U.S. District Court for the Eastern District of New York, accuses Novo Nordisk of using patent tactics to delay the entry of generic versions of Victoza into the market, thereby maintaining its dominance and preventing competition.

The complaint alleges that Novo Nordisk’s actions have harmed consumers by keeping drug prices artificially high and limiting access to more affordable generic alternatives.

The class action is seeking damages for consumers who have purchased Victoza at allegedly inflated prices due to Novo Nordisk’s anticompetitive conduct.

Novo Nordisk has not yet publicly responded to the allegations.

For more information, refer to the attached Complaint document.